|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Target and Lead Validation |
|
|
|
|
€ 1 400,00 |
Editeur
: |
ZZZ - Biovista |
Langue
: |
Anglais |
Date de publication : |
Décembre 2000 |
Taille du document : |
160 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Functional Proteomics and Emerging Bio-IT market
pages | Novembre 2002 |
The proteomic technique is not only limited to the study of one or few cellular products but also allows for qualitative and a quantitative measurement of several hundreds of proteins produced during |
250,00 €
|
| |
| |
03-052B: The DNA Purification Market: Keys to Success for Commercial Kit Suppliers
152 pages | Octobre 2003 |
This report is designed to help life science product managers understand customers in the DNA purification market and the factors that drive their purchasing behavior |
1 280,00 €
|
| |
| |
03-052A: Protein Purification Systems: Market Opportunities for Research Product Suppliers
163 pages | Octobre 2003 |
This report will help suppliers exploit opportunities to differentiate themselves from their competitors and develop more advanced protein purification tools |
960,00 €
|
| |
| |
Genomic Revolution: Trends & Opportunities
30 pages | Octobre 2002 |
Computational advancements in Genomic technology have brought a revolution in the field of application of Pharmaco-Therapy.
Companies are diversifying their business prospect from medical chemistry |
600,00 €
|
| |
| |
Carbohydrate Therapeutics
180 pages | Décembre 2000 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 400,00 €
|
| |
| |
Antisense Therapeutics IRCD
pages | Juin 2001 |
Antisense molecules are stretches of single-stranded nucleic acid that target and bind with a specific mRNA, interfering with and even preventing the translation or over-expression of the protein |
1 026,17 €
|
| |
| |
03-026: The Market for Tissue Microarrays
134 pages | Juillet 2003 |
This report provides vital information on end-users’ scientific objectives, instrumentation for production and analysis of TMAs, outsourcing practices and preferred TMA suppliers |
640,00 €
|
| |
| |
Integrating Genomics: The Next Generation
124 pages | Février 1999 |
Genomics research : Understand the key technologies including target identification (genome mapping, random sequencing and two-hybrid assay), target validation/assay development and current appli |
795,00 €
|
| |
| |
Pharmacogenomics
160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications
183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Target and Lead Validation |
|
|
The advent of brute force approaches to lead generation has highlighted a key
bottleneck in drug development. The issue is not how many new compounds can
one make per day, but rather how many can one validate or legitimize as potential
therapeutic candidates for further development. This is the lead validation
problem of drug discovery, and whoever has technologies that can readily screen
many compounds and provide even a 70% accurate continue/discontinue prediction
will be very successful.
At present, high throughput screening, which attempts to address this issue,
is based mostly on one-to-one binding assays, where a target of interest, say
HIV protease, is exposed to potential inhibitors in a high throughput enzyme
function test. Although a priori this approach makes sense and forms the cornerstone
of current validation programs, its accuracy is fundamentally constrained by
the assumption that a good in vitro inhibitor of HIV protease in the previous
example will also arrest HIV growth in a patient setting.
The next generation of high throughput lead validation platforms may be based
on combinations of automated cellular assays, and cell-free "molecular
drug response cascades".
|
|
Executive Summary
Aims and Scope
IRCD Structure
PART 1: TECHNOLOGY SUMMARY
Background
The Target and Lead Validation Problem
Evolution of the Field
The Yeast Two-Hybrid System
The Impact of Genomics
State of the Art
Development Issues
Future Developments
Technology Examples
Genelabs Technologies: MERLIN ™
Acadia Pharmaceuticals: R-SAT™
Acacia Biosciences: Genome Reporter Matrixa
Genzyme Molecular Oncology: SAGE
Exelixis Pharmaceuticals: PathFindera
Genaissance Pharmaceuticals: Clasper Systema
Small Molecule Therapeutics: FISTa
PART 2: BUSINESS DEVELOPMENT
Platform Biotechnologies Current Conditions Market Size Estimates Synopsis of Notable Events in 1998-1999 (YTD)
Descriptions of Corporate Activities in 1998-1999 (YTD)
Discussion of Corporate Activities in 1998-1999 (YTD)
Mergers, Acquisitions and Spin-Out's.
Biochip Technology Access Programs
Target Identification and Validation Collaborations.
Validation of Non-Human Targets.
Target Validation and Disease Relevance.
PART 3: COMPANY DATABASE
Methodology
Concise Company Listing
Extended Company Listing
PART 4: PATENTS DATABASE
Methodology
Concise Patent Listing
|
|
|
PPLSEN
|
|
|
|
|
